Literature DB >> 12459476

Cellular activation of proMMP-13 by MT1-MMP depends on the C-terminal domain of MMP-13.

Vera Knäuper1, Louise Bailey, Joanna R Worley, Paul Soloway, Margaret L Patterson, Gillian Murphy.   

Abstract

Procollagenase-3 (proMMP-13) can be activated by soluble or cell associated membrane type matrix metalloproteinase 1 (MT1-MMP). In this study we show that the cell based activation of proMMP-13 by MT1-MMP was dependent on the C-terminal domain, as delta(249-451) proMMP-13, which lacks the haemopexin domain, and a chimaera from N-terminal MMP-13 and C-terminal MMP-19 (proMMP-13/19) were not processed by MT1-MMP expressing cells. Only the initial cleavage at Gly(35)-Ile(36) was dependent on MT1-MMP activity, as conversion to the active enzyme (Tyr(85) N-terminus) required a functional MMP-13 active site. Unlike proMMP-2 activation, this process was independent of tissue inhibitor of metalloproteinase-2 (TIMP-2) as MT1-MMP expressing cells from the TIMP-2-/- mouse efficiently activated proMMP-13.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12459476     DOI: 10.1016/s0014-5793(02)03654-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  38 in total

Review 1.  Lectican proteoglycans, their cleaving metalloproteinases, and plasticity in the central nervous system extracellular microenvironment.

Authors:  M D Howell; P E Gottschall
Journal:  Neuroscience       Date:  2012-05-22       Impact factor: 3.590

Review 2.  Matrix metalloproteases: underutilized targets for drug delivery.

Authors:  Deepali G Vartak; Richard A Gemeinhart
Journal:  J Drug Target       Date:  2007-01       Impact factor: 5.121

3.  Imaging with radiolabelled anti-membrane type 1 matrix metalloproteinase (MT1-MMP) antibody: potentials for characterizing atherosclerotic plaques.

Authors:  Yuji Kuge; Nozomi Takai; Yuki Ogawa; Takashi Temma; Yan Zhao; Kantaro Nishigori; Seigo Ishino; Junko Kamihashi; Yasushi Kiyono; Masashi Shiomi; Hideo Saji
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-13       Impact factor: 9.236

4.  MMP protein and activity levels in synovial fluid from patients with joint injury, inflammatory arthritis, and osteoarthritis.

Authors:  I Tchetverikov; L S Lohmander; N Verzijl; T W J Huizinga; J M TeKoppele; R Hanemaaijer; J DeGroot
Journal:  Ann Rheum Dis       Date:  2005-05       Impact factor: 19.103

5.  Radiolabelled probes for imaging of atherosclerotic plaques.

Authors:  Takashi Temma; Hideo Saji
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-10-15

6.  IFNγ and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma.

Authors:  Kristen B Long; Whitney L Gladney; Graham M Tooker; Kathleen Graham; Joseph A Fraietta; Gregory L Beatty
Journal:  Cancer Discov       Date:  2016-02-19       Impact factor: 39.397

7.  Acetylsalicylic acid combined with diclofenac inhibits cartilage degradation in rabbit models of osteoarthritis.

Authors:  Jianqiang Liu; Changshun Wu; Dong Wang; Laicheng Wang; Shui Sun
Journal:  Exp Ther Med       Date:  2016-08-01       Impact factor: 2.447

8.  New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies.

Authors:  Laetitia Devy; Daniel T Dransfield
Journal:  Biochem Res Int       Date:  2010-10-28

Review 9.  Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy.

Authors:  Alex Y Strongin
Journal:  Biochim Biophys Acta       Date:  2009-05-04

Review 10.  Membrane type 1-matrix metalloproteinase: substrate diversity in pericellular proteolysis.

Authors:  Maria V Barbolina; M Sharon Stack
Journal:  Semin Cell Dev Biol       Date:  2007-07-10       Impact factor: 7.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.